Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.
Maione A, Navaneethan SD, Graziano G, Mitchell R, Johnson D, Mann JF, Gao P, Craig JC, Tognoni G, Perkovic V, Nicolucci A, De Cosmo S, Sasso A, Lamacchia O, Cignarelli M, Manfreda VM, Gentile G, Strippoli GF. Maione A, et al. Nephrol Dial Transplant. 2011 Sep;26(9):2827-47. doi: 10.1093/ndt/gfq792. Epub 2011 Mar 3. Nephrol Dial Transplant. 2011. PMID: 21372254 Review.
The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.
Saglimbene V, Palmer SC, Ruospo M, Natale P, Maione A, Nicolucci A, Vecchio M, Tognoni G, Craig JC, Pellegrini F, Lucisano G, Hegbrant J, Ariano R, Lamacchia O, Sasso A, Morano S, Filardi T, De Cosmo S, Pugliese G, Procaccini DA, Gesualdo L, Palasciano G, Johnson DW, Tonelli M, Strippoli GFM; Long-Term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) Investigators. Saglimbene V, et al. Among authors: maione a. J Am Soc Nephrol. 2018 Dec;29(12):2890-2899. doi: 10.1681/ASN.2018040443. Epub 2018 Nov 12. J Am Soc Nephrol. 2018. PMID: 30420421 Free PMC article. Clinical Trial.
[Angiotensin converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in microalbuminuric patients with one or more cardiovascular risk factors. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes randomized trial (LIRICO).].
Maione A, Nicolucci A, Craig JC, Tognoni G, Moschetta A, Palasciano G, Pugliese G, Procaccini DA, Gesualdo L, Pellegrini F, Strippoli GF. Maione A, et al. G Ital Nefrol. 2007 Sep-Oct;24(5):446-56. G Ital Nefrol. 2007. PMID: 17886213 Clinical Trial. Italian.
Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.
Strippoli GF; Clinical Evaluation of the DOse of Erythropoietins Study Group (C.E. DOSE). Strippoli GF, et al. Trials. 2010 Jun 9;11:70. doi: 10.1186/1745-6215-11-70. Trials. 2010. PMID: 20534124 Free PMC article. Clinical Trial.
Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin.
Evangelista V, de Berardis G, Totani L, Avanzini F, Giorda CB, Brero L, Levantesi G, Marelli G, Pupillo M, Iacuitti G, Pozzoli G, di Summa P, Nada E, de Simone G, Dell'Elba G, Amore C, Manarini S, Pecce R, Maione A, Tognoni G, Nicolucci A. Evangelista V, et al. Among authors: maione a. J Thromb Haemost. 2007 Nov;5(11):2197-203. doi: 10.1111/j.1538-7836.2007.02728.x. Epub 2007 Aug 7. J Thromb Haemost. 2007. PMID: 17697141 Free article. Clinical Trial.
153 results